CGON

CG Oncology (CGON)

About CG Oncology (CGON)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Details

Daily high

$70.32

Daily low

$68.55

Price at open

$68.90

52 Week High

$73.56

52 Week Low

$23.32

Market cap

5.8B

Dividend yield

0.00%

Volume

1.1M

Avg. volume

947,951

P/E ratio

-33.22

CG Oncology News